INNOPREFAT SIGNED
Natural Food formulation for the prevention and treatment the Obesity and Metabolic Syndrome obtained with herbal extracts
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0INNOPREFAT project word cloud
Explore the words cloud of the INNOPREFAT project. It provides you a very rough idea of what is the project "INNOPREFAT" about.
Project "INNOPREFAT" data sheet
The following table provides information about the project.
| Coordinator |
MONTELOEDER SL
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Project website | https://www.monteloeder.com/en/innoprefat |
| Total cost | 1˙484˙128 € |
| EC max contribution | 1˙038˙889 € (70%) |
| Programme |
1. H2020-EU.3.2.4. (Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy) 2. H2020-EU.3.2.1. (Sustainable agriculture and forestry) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.3.2.2. (Sustainable and competitive agri-food sector for a safe and healthy diet) |
| Code Call | H2020-SMEINST-2-2016-2017 |
| Funding Scheme | SME-2 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-10-01 to 2020-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | MONTELOEDER SL | ES (ELCHE) | coordinator | 1˙038˙889.00 |
Map
Project objective
Monteloeder is a global developer, manufacturer and distributor of ingredients and formulations for the nutrition and cosmetics industry. It is committed to identifying and developing safe and effective ingredients derived from natural plants that deliver measureable benefits to consumers. Founded in 1996, Monteloeder today has sales in more than 38 countries and operates offices in Europe, US and Asia.
INNOPREFAT is the result of a long process led by Monteloeder to discover a natural solution to address one of the major epidemics of our time: Metabolic Syndrome (MetS). MetS can lead to serious diseases and conditions, including diabetes type-2, stroke, Alzheimer’s, cancer and heart disease. It affects more than 25% of the world’s population and represents a major and escalating global public health problem and clinical challenge. In Europe, about 8-18% of total adult healthcare expenditure is metabolic syndrome related.
The Business Model and the solution (MetabolAid®) are built around three dimensions: 1. A superior quality product based on a synergistic blend of two herbal extracts, which is supported by an extensive and rigorous scientific programme that demonstrates its effectiveness in improving MetS, as well as its safety and its economic viability. 2. A fully traceable, transparent and efficient supply chain, which guarantees that the product is natural, sustainably produced, completely safe and that it can be included in the main food matrices. 3. Global marketing approach includes a novel and original strategy: we will support our B2B clients with mobile phone health technology to manage end-consumer’s experience with the product and improve their levels of compliance, which in turn will enhance efficacy.
Monteloeder believes that those are the dimensions that will determine how ingredients must be designed, developed, produced and marketed to address the big changes in consumer preferences that are already taking place in the market.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Young-Sil Lee, Won-Kyung Yang, Hwa Kim, Bokkee Min, Nuria Caturla, Jonathan Jones, Yang-Chun Park, Young-Cheol Lee, Seung-Hyung Kim Metabolaid® Combination of Lemon Verbena and Hibiscus Flower Extract Prevents High-Fat Diet-Induced Obesity through AMP-Activated Protein Kinase Activation published pages: 1204, ISSN: 2072-6643, DOI: 10.3390/nu10091204 |
Nutrients 10/9 | 2019-09-18 |
| 2018 |
Marina Boix-Castejón, MarÃa Herranz-López, Alberto Pérez Gago, Mariló Olivares-Vicente, Nuria Caturla, Enrique Roche, Vicente Micol Hibiscus and lemon verbena polyphenols modulate appetite-related biomarkers in overweight subjects: a randomized controlled trial published pages: 3173-3184, ISSN: 2042-650X, DOI: 10.1039/c8fo00367j |
Food & Function 9/6 | 2019-09-18 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INNOPREFAT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "INNOPREFAT" are provided by the European Opendata Portal: CORDIS opendata.